Dermatophyte test medium culture for evaluating toenail infections in patients with diabetes

Diabetes Care

Volumn 26, Issue 5, 2003, Pages 1480-1484

  Rich, Phoebe ^a,e   Harkless, Lawrence B ^b   Atillasoy, Ercem S ^c,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; POTASSIUM HYDROXIDE;

ADULT; ARTICLE; CULTURE MEDIUM; CULTURE TECHNIQUE; DERMATOPHYTE; DIABETES MELLITUS; DRUG EFFICACY; FUNGUS CULTURE; FUNGUS IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; MCNEMAR TEST; MYCOLOGY; MYCOSIS; NAIL INFECTION; NONHUMAN; ONYCHOMYCOSIS; PATHOGENESIS; SENSITIVITY ANALYSIS; SKIN TEST; STATISTICAL SIGNIFICANCE; TOE;

ARTHRODERMATACEAE; CULTURE MEDIA; DERMATOLOGY; DIABETES COMPLICATIONS; DIABETES MELLITUS; FAMILY PRACTICE; HUMANS; NAILS; ONYCHOMYCOSIS; PODIATRY;

EID: 0042168767     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.5.1480     Document Type: Article

References (31)

1. Gupta AK, Konnikov N, MacDonald P, Rich P, Rodger NW, Edmonds MW, McManus R, Summerbell RC: Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 139:665-671, 1998
2. Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, Sullivan S, Daniel R, Krusinski P, Fleckman P, Rich P, Odom R, Aly R, Pariser D, Zaiac M, Rebell G, Lesher J, Gerlach B, Ponce-DeLeon GF, Ghannoum A, Wamer J, Isham N, Elewski B: A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 43:641-648, 2000
3. Boyko WL, Doyle JJ, Ryu S, Gause D: Onychomycosis and its impact on secondary infection development in the diabetic population (Poster). Presented at the 4th annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA, 23-26 May 1999
4. Greene RA, Scher RK: Nail changes associated with diabetes mellitus. J Am Acad Dermatol 16:1015-1021, 1987
5. Levy LA: Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc 87:546-550, 1997
6. Rich P: Special patient populations: onychomycosis in the diabetic patient. J Am Acad Dermatol 35:S10-S12, 1996
7. Rich P, Hare A: Onychomycosis in a special patient population: focus on the diabetic. Int J Dermatol 38 (Suppl. 2):17-19, 1999
8. Drake LA, Scher RK, Smith EB, Faich GA, Smith SL, Hong JJ, Stiller MJ: Effect of onychomycosis on quality of life. J Am Acad Dermatol 38:702-704, 1998
9. Lubeck DP: Measuring health-related quality of life in onychomycosis. J Am Acad Dermatol 38:S64-S68, 1998
10. Schein JR, Gause D, Stier DM, Lubeck DP, Bates MM, Fisk R: Onychomycosis: baseline results of an observational study. J Am Podiatr Med Assoc 87:512-519, 1997
11. Evans EG: Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 38:S32-S36, 1998
12. Kemna ME, Elewski BE: A U.S. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol 35:539-542, 1996
13. Summerbell RC: Epidemiology and ecology of onychomycosis. Dermatology 194 (Suppl. 1):32-36, 1997
14. Elewski BE: Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 11:415-429, 1998
15. Gupta AK, Shear NH: The new oral antifungal agents for onychomycosis of the toenails. J Eur Acad Derm Venereol 13:1-13, 1999
16. Niewerth M, Korting HC: Management of onychomycoses. Drugs 58:283-296, 1999
17. Elewski BE: Diagnostic techniques for confirming onychomycosis. J Am Acad Dermatol 35:S6-S9, 1996
18. Pierard GE, Arrese JE, De Doncker P, Pierard-Franchimont C: Present and potential diagnostic techniques in onychomycosis. J Am Acad Dermatol 34:273-277, 1996
19. Taplin D, Zaias N, Rebell G, Blank H: Isolation and recognition of dermatophytes on a new medium (DTM). Arch Dermatol 99:203-209, 1969
20. Gupta AK, Humke S: The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol 10:379-384, 2000
21. Feinstein AR: Clinimetrics. New Haven, CT, Yale University Press, 1987
22. Stokes ME, Davis CE, Koch GG: Categorical Data Analysis Using the SAS Software. 2nd ed. Cary, NC, SAS Institute, 2000
23. Daniel CR III, Elewski B: The diagnosis of nail fungus infection, revisited. Arch Dermatol 136:1162-1164, 2000
24. Elewski BE, Leyden J, Rinaldi M, Atillasoy E: Office-based confirmation of onychomyosis: a U.S. prospective survey. Arch Intern Med 162:2133-2138, 2002
25. Albreski DA, Gupta AK, Gross EG: Onychomycosis in diabetes: management considerations (Review). Postgrad Med (Spec. no.):26-30, 1999
26. Elewski BE: Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the Multicenter Onychomycosis Study of Terbinafine (Letter). Arch Dermatol 133: 1317-1318, 1997
27. Gupta AK, Jain HC, Lynde CW, MacDonald P, Cooper EA, Summerbell RC: Prevalence and epidemiology of onychomycosis in patients visiting physicians offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 43:244-248, 2000
28. Harvey CK, Richardson A: Techniques for obtaining specimens for culture to confirm onychomycosis. J Am Podiatr Assoc 90:394-396, 2000
29. Farkas B, Paul C, Dobozy A, Hunyadi J, Horvath A, Fekete G: Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol 146:254-260, 2002
30. Hall M, Monka C, Krupp P, O'Sullivan D: Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol 133:1213-1219, 1997
31. Verspeelt J, Marynissen G, Gupta AK, De Doncker P: Safety of itraconazole in diabetic patients. Dermatology 198:382-384, 1999